An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover BE Study of SITAGAVIA (100 mg) of the GPO, Thailand with Januvia of ORGANON PHARMA (UK) LIMITED, United Kingdom in Normal, Healthy, Adult Human Subjects under Fasting Conditions
- Conditions
- Healthy male and female subjectsBioequivalence fed conditions
- Registration Number
- TCTR20231101008
- Lead Sponsor
- The Government Pharmaceutical Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 30
1. Normal, healthy, adult, both males and females subjects between 18 and 55 years of age (both inclusive).
2. Having a Body Mass Index (BMI) between 18.0 and 30.0 (both inclusive), calculated as weight in kg/height in m2.
3. Subject whose clinical laboratory values are within normal/acceptable reference ranges or clinically insignificant during screening as determined by physician or principal investigator to be of no clinical significance. If any subject has values outside of the pre-defined normal/acceptable range, the study physician/ Principal Investigator should have a clearly documented and medically rigorous justification for making that exception.
4. Subject whose medical history, clinical examination, 12 lead ECG, and chest X-ray recordings (postero-anterior view) are normal or clinically insignificant during screening as determined by physician or principal investigator to be of no clinical significance.
5. Able to understand and comply with the study procedures, in the opinion of the investigator.
6. Able to give voluntary written informed consent for participation in the trial.
7. In case of female subjects:
- Surgically sterilized at least 06 months prior to study participation;
Or
- If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.
And
- Urine pregnancy test must be negative.
1. Known hypersensitivity to sitagliptin such as anaphylaxis or angioedema or any excipients or any related drug or any substance.
2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
3. Subjects who are being or have previously been treated for any GI problems or convulsive, depressive or hepatic disorders, and in whom there is a risk of a recurrence during the study period.
4. Ingestion or use of any medication (prescribed medication and over the counter (OTC) medication including herbal remedies and St. John Wort) at any time in 14 days prior to dosing of period-I. In any such case subject selection will be at the discretion of the Principal Investigator.
5. Any history of bronchospasm, asthma, urticaria or other allergic type reactions after taking any medication.
6. Consumption of grapefruits and grapefruit products within a period of 72 hours prior to dosing in Period-I.
7. Consumption of xanthine containing food or beverages (tea, coffee, chocolates or cola drinks) 24 hours prior to IMP administration of period-I.
8.Heavy smoking (greater than or equal to 10 cigarettes/day).
9. Moderate smoking (Less 10 cigarettes/day) and consumption of tobacco containing products, which cannot stop smoking or consuming 24 hours prior to dosing and for entire duration of the study.
10. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40 percent distilled spirits, such as rum, whisky, brand.) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period-I.
11.The presence of clinically significant abnormal laboratory values during screening.
12. Use of any recreational drugs or history of drug addiction or testing positive in pre study drug scans.
13. History or presence of seizure or psychiatric disorder.
14. A history of difficulty with donating blood.
15. Difficulty in swallowing solids dosage forms like tablets or capsules.
16. Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
17. Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.
** If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.
18. A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
19. A positive test result for HIV antibody.
20. A positive test result for COVID-19 RT-PCR test through the nasopharyngeal swab.
21. An unusual diet, for whatever reason (for example, fasting, high potassium or low-sodium), for four weeks prior to receiving the study drug in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
22. Nursing mothers (for female subjects).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome Name Metric/Method of measurement Time point Options 90 % CI pharmacokinetic parameters derived from drug plasma The venous blood samples will be withdrawn pre-dose (0.000 hour) and at 0.3, 0.6, 1, 1.3, 1.6, 2, 2.3, 2.6, 3, 3.3, 3.6, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose bioanalysis and pharmacokinetic data analysis
- Secondary Outcome Measures
Name Time Method Adverse event/severe adverse event Vitals (Sitting Blood pressure, respiratory rate and pulse rate) will be recorded at pre-dose and at 01, 02, 04, 06, 08, 12, 24, 36, 48 and 72 hours post-dose in each period. physical and biochemical examination